Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/06/26 01:50:54」(JST)

wiki en

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Pharmacology

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Contraindications

Nateglinide is contraindicated in patients who:

have known hypersensitivity to the compound or any ingredient in the formulation.
are affected with type 1 (namely insulin-dependent) diabetes mellitus.
are in diabetic ketoacidosis.

Comparisons with other drugs for type 2 diabetes

A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial".^[1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."

Dosage

Nateglinide is delivered in 60 mg & 120 mg tablet form.

References

^ Rosenstock, Julio Rosenstock; Hassman, David R.; Madder, Robert D.; Brazinsky, Shari A.; Farrell, James; Khutoryansky, Naum; Hale, Paula M. (June 2004), "Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study", Diabetes Care (American Diabetes Association) 27 (6): 1265–1270, doi:10.2337/diacare.27.6.1265, retrieved 2014-11-20

External links

Starlix - website of the manufacturer.
How Nateglinide Works - website of the manufacturer.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 2型糖尿病の予防 prevention of type 2 diabetes mellitus
2. 糖尿病の治療におけるスルホニル尿素およびメグリチニド sulfonylureas and meglitinides in the treatment of diabetes mellitus
3. 高齢患者における2型糖尿病の治療 treatment of type 2 diabetes mellitus in the elderly patient
4. 2型糖尿病における持続性高血糖のマネージメント management of persistent hyperglycemia in type 2 diabetes mellitus
5. 透析前慢性腎臓病または末期腎不全を伴う2型糖尿病患者における高血糖の
マネージメント management of hyperglycemia in patients with type 2 diabetes and pre dialysis chronic kidney disease or end stage renal disease

English Journal

Rapid, sensitive and selective HPLC-MS/MS method for the quantification of topically applied besifloxacin in rabbit plasma and ocular tissues: Application to a pharmacokinetic study.

Gu XF1, Mao BY2, Xia M3, Yang Y3, Zhang JL3, Yang DS3, Wu WX3, Du YX4, Di B5, Su MX6.
Journal of pharmaceutical and biomedical analysis.J Pharm Biomed Anal.2016 Jan 5;117:37-46. doi: 10.1016/j.jpba.2015.08.023. Epub 2015 Aug 22.
Besifloxacin is a fourth-generation broad-spectrum fluoroquinolone registered for the topical treatment of bacterial conjunctivitis. In this study, a rapid, sensitive and selective liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed for quantification of besifloxacin in ra
PMID 26340560

Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study.

Tostes GC1, Cunha MR1, Fukui RT1, Correia MR1, Rocha DM1, Dos Santos RF1, da Silva ME1.
Diabetology & metabolic syndrome.Diabetol Metab Syndr.2016 Jan 4;8:1. doi: 10.1186/s13098-015-0120-6. eCollection 2016.
BACKGROUND: To compare the effects of nateglinide and rosiglitazone on inflammatory markers, GLP-1 levels and metabolic profile in patients with type 2 diabetes (DM2).METHODS: A prospective study was performed in 20 patients with DM2, mean age 51.82 ± 8.05 years, previously treated with dietary
PMID 26734075

Preparation of polyclonal antibodies for nateglinide (NTG) and development of a sensitive chemiluminescent immunoassay to detect NTG in tablets and serum.

Zheng L1, Wang J1, Zhang J2, Song Z1, Dong Y1, Wang Y1, Tong Z2, Deng C3, Yin Y1, Meng M4, Xi R1.
Talanta.Talanta.2016 Jan 1;146:483-9. doi: 10.1016/j.talanta.2015.09.008. Epub 2015 Sep 9.
In this study, we prepared polyclonal antibodies against anti-diabetic drug nateglinide (NTG), and established a sensitive chemiluminescent immunoassay (CLIA) to detect NTG in tablets and serum. Two kinds of immunogens were synthesized using ethylcarbodiimide (EDC)/hydroxysuccinimide (NHS) and carbo
PMID 26695294

Japanese Journal

慢性移植片対宿主病による皮膚障害に対してインスリン皮下注射実施に工夫を要したステロイド糖尿病の1例

糖尿病 58(8), 558-563, 2015
NAID 130005095258

Complex Formation with Layered Double Hydroxides for the Remediation of Hygroscopicity

Chemical and Pharmaceutical Bulletin 63(1), 13-17, 2015
NAID 130004803753

多疾患併発の高齢者に対する多剤併用薬物療法中に出現した薬剤性肝障害の一例

東北薬科大学研究誌 61, 65-70, 2014-12
NAID 110009901332

Related Pictures

★リンクテーブル★

リンク元

「ナテグリニド」

Nateglinide
Systematic (IUPAC) name
	(2R)-2-({[trans-4-(1-methylethyl)cyclohexyl]carbonyl}amino)-3-phenylpropanoic acid
Clinical data
Trade names	Starlix
AHFS/Drugs.com	monograph
MedlinePlus	a699057
Licence data	EMA:Link, US FDA:link
Legal status	UK: Prescription-only (POM); US: ℞-only;
Routes of; administration	Oral
Pharmacokinetic data
Protein binding	98%
Biological half-life	1.5 hours
Identifiers
CAS Registry Number	105816-04-4
ATC code	A10BX03
PubChem	CID: 60026
IUPHAR/BPS	6833
DrugBank	DB00731
ChemSpider	10482084
UNII	41X3PWK4O2
KEGG	D01111
ChEBI	CHEBI:31897
ChEMBL	CHEMBL286559
Chemical data
Formula	C19H27NO3
Molecular mass	317.423 g/mol
	SMILES O=C(N[C@H](Cc1ccccc1)C(O)=O)[C@H]2CC[C@@H](CC2)C(C)C;
	InChI InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1 ; Key:OELFLUMRDSZNSF-BRWVUGGUSA-N ;
(what is this?) (verify)

　　[★]

英: nateglinide
商: スターシス、ファスティック
関: 糖尿病治療薬、薬理学、グリニド系薬

概念

糖尿病治療薬、速効型インスリン分泌促進

利点

食後高血糖を改善する (α-GIより強力)
インスリンの遅延過剰反応を抑制する
一日の血糖変動幅が小さい
低血糖を比較的起こしにくい (GOO.1638)
軽症糖尿病に使いやすい
肥満患者にも使える

作用機序

スルホニル尿酸系薬と同様

[1] Rosenstock, Julio Rosenstock; Hassman, David R.; Madder, Robert D.; Brazinsky, Shari A.; Farrell, James; Khutoryansky, Naum; Hale, Paula M. (June 2004), "Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study", Diabetes Care (American Diabetes Association) 27 (6): 1265–1270, doi:10.2337/diacare.27.6.1265, retrieved 2014-11-20

匿名

検索

案内

案内

nateglinide